CY1113641T1 - Φαρμακευτικη συνθεση που περιλαμβανει aleglitazar - Google Patents

Φαρμακευτικη συνθεση που περιλαμβανει aleglitazar

Info

Publication number
CY1113641T1
CY1113641T1 CY20121101181T CY121101181T CY1113641T1 CY 1113641 T1 CY1113641 T1 CY 1113641T1 CY 20121101181 T CY20121101181 T CY 20121101181T CY 121101181 T CY121101181 T CY 121101181T CY 1113641 T1 CY1113641 T1 CY 1113641T1
Authority
CY
Cyprus
Prior art keywords
aleglitazar
pharmaceutical composition
composition including
manufacturing process
relates
Prior art date
Application number
CY20121101181T
Other languages
English (en)
Inventor
Alexander Glomme
Paul Wojtera
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1113641T1 publication Critical patent/CY1113641T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Η εφεύρεση σχετίζεται με μια φαρμακευτική σύνθεση που περιλαμβάνει aleglitazar και με τη διαδικασία παρασκευής και με χρήσεις αυτής.
CY20121101181T 2009-01-23 2012-12-03 Φαρμακευτικη συνθεση που περιλαμβανει aleglitazar CY1113641T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151254 2009-01-23
EP10701340A EP2389166B1 (en) 2009-01-23 2010-01-13 Pharmaceutical composition comprising aleglitazar

Publications (1)

Publication Number Publication Date
CY1113641T1 true CY1113641T1 (el) 2016-06-22

Family

ID=42112184

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101181T CY1113641T1 (el) 2009-01-23 2012-12-03 Φαρμακευτικη συνθεση που περιλαμβανει aleglitazar

Country Status (25)

Country Link
US (2) US20100190835A1 (el)
EP (1) EP2389166B1 (el)
JP (1) JP5619027B2 (el)
KR (2) KR20140002812A (el)
CN (1) CN102292074B (el)
AR (1) AR075041A1 (el)
AU (1) AU2010206249B2 (el)
BR (1) BRPI1007237B1 (el)
CA (1) CA2748896C (el)
CL (1) CL2011001777A1 (el)
CY (1) CY1113641T1 (el)
DK (1) DK2389166T3 (el)
ES (1) ES2397558T3 (el)
HR (1) HRP20130108T1 (el)
IL (1) IL213671A (el)
MX (1) MX2011007381A (el)
PE (2) PE20160746A1 (el)
PL (1) PL2389166T3 (el)
PT (1) PT2389166E (el)
RU (1) RU2537224C2 (el)
SG (1) SG173058A1 (el)
SI (1) SI2389166T1 (el)
TW (1) TWI406861B (el)
WO (1) WO2010084066A1 (el)
ZA (1) ZA201104670B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
WO2014016370A1 (en) * 2012-07-27 2014-01-30 Ratiopharm Gmbh Amorphous aleglitazar
WO2014016369A1 (en) 2012-07-27 2014-01-30 Ratiopharm Gmbh Pharmaceutical formulation comprising aleglitazar and complexing agent
WO2014016371A1 (en) 2012-07-27 2014-01-30 Ratiopharm Gmbh Micronized aleglitazar
BR112015005350A2 (pt) * 2012-09-12 2017-07-04 Hoffmann La Roche formas sólidas de (s)-2-metoxi-3-{4-[2-(5-metil-2-feniloxazol-4-ila)-etoxi]-benzo[b]tiofen-7-ila}-ácido propiônico e/ou sais do mesmo
JP6875501B2 (ja) 2016-08-10 2021-05-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ａｋｔプロテインキナーゼ阻害剤を含む薬学的組成物
CN114404375B (zh) * 2022-01-21 2023-06-27 武汉九珑人福药业有限责任公司 一种叶酸固体制剂及其原料组合物、制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
ES2264482T3 (es) * 2001-05-15 2007-01-01 F. Hoffmann-La Roche Ag Derivados de oxazol sustituidos por acido carboxilico para uso como activadores de ppar-alfa y gamma en el tratamiento de diabetes.
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
EP1855655A2 (en) * 2005-02-25 2007-11-21 F. Hoffmann-Roche AG Tablets with improved drug substance dispersibility
US20060270722A1 (en) * 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
FR2894477A1 (fr) * 2005-12-13 2007-06-15 Galderma Res & Dev Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
WO2008119070A1 (en) * 2007-03-28 2008-10-02 Trustees Of Boston University Methods of treatment using sirt modulators and compositions containing sirt1 modulators

Also Published As

Publication number Publication date
PL2389166T3 (pl) 2013-04-30
RU2537224C2 (ru) 2014-12-27
CA2748896C (en) 2017-01-03
AU2010206249A1 (en) 2011-06-30
KR20140002812A (ko) 2014-01-08
DK2389166T3 (da) 2012-12-17
CN102292074A (zh) 2011-12-21
EP2389166B1 (en) 2012-11-21
TW201035089A (en) 2010-10-01
ES2397558T3 (es) 2013-03-07
AR075041A1 (es) 2011-03-02
RU2011134964A (ru) 2013-02-27
US20130072529A1 (en) 2013-03-21
IL213671A (en) 2015-11-30
MX2011007381A (es) 2011-08-12
AU2010206249B2 (en) 2015-07-09
JP5619027B2 (ja) 2014-11-05
BRPI1007237B1 (pt) 2019-05-28
CL2011001777A1 (es) 2012-02-24
ZA201104670B (en) 2012-03-28
HRP20130108T1 (hr) 2013-03-31
KR20110105798A (ko) 2011-09-27
PT2389166E (pt) 2013-01-08
EP2389166A1 (en) 2011-11-30
CN102292074B (zh) 2013-08-21
JP2012515741A (ja) 2012-07-12
SI2389166T1 (sl) 2013-02-28
WO2010084066A1 (en) 2010-07-29
IL213671A0 (en) 2011-07-31
US20100190835A1 (en) 2010-07-29
PE20160746A1 (es) 2016-08-01
TWI406861B (zh) 2013-09-01
BRPI1007237A2 (pt) 2016-02-16
PE20120421A1 (es) 2012-05-04
CA2748896A1 (en) 2010-07-29
SG173058A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
CY2018030I1 (el) Φαρμακοτεχνικη μορφη 514
CY1113641T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει aleglitazar
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CY1117479T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1115595T1 (el) Αλατα ρασιγιλινης και φαρμακευτικη παρασκευη αυτων
BRPI0917193A2 (pt) composição polimérica, artigo de fabricação, e, método de produzir uma composição polimérica.
BRPI1012892A2 (pt) composto, e, composição farmacêutica.
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
CY1115381T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη
BRPI0906611A2 (pt) Produtos implantáveis compreendendo nanopartículas.
BRPI0920428A2 (pt) inalador.
CY1122115T1 (el) Παραγωγα ν1-ακυλο-5-φθοροπυριμιδινονης
GT201200284A (es) Composición farmacéutica
CY1114190T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
CY1122711T1 (el) Μεθοδος για την ενεργοποιηση και τη συζευξη βιομοριων
CR20110403A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia
BRPI0911889A2 (pt) composição termoplástica, artigo de manufatura e método de formar uma composição termoplástica
BRPI0914182A2 (pt) composto, e, composição farmacêutica
GR1007010B (el) Ινσουλινοειδη πεπτιδια
CU24011B1 (es) Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
CY1113835T1 (el) Δραση των εκχυλισματων του φυτου cissampelos pareira εναντι του δαγκειου πυρετου